VTGN: VistaGen Therapeutics Inc Total Debt to Capital
Vistagen Therapeutics (VTGN) is implementing eco-friendly closed-loop water consumption cycles to minimize environmental impact. The share price retrospective on GURU.Markets shows that the individual debt-to-equity ratio is 0.03. Financial stability is based on patents for the creation of fast-acting anxiety sprays, while the operating model relies on the full outsourcing of production and testing to external contractors.
%20-%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261101&filename=GURU_Markets_-_VTGN_-_Vistagen-Therapeutics_-_Debt-to-Capital "Total Debt to Equity Ratio: Vistagen (VTGN) for 07/04/2022 - 11/01/2026 | 👁️GURU.Markets👁️")
Metric breakdowns and analytics for Vistagen (VTGN)
- price and consensus price forecast:
- market capitalization information:
- book capitalization indicators:
- issuer credit burden and liquidity indicators:
- earnings and market ratios statistics:
Summary company analysis:Vistagen Therapeutics, VTGN
To identify fundamental benchmarks in Vistagen Therapeutics (VTGN) financial statements, it is critical to evaluate the financing structure via the total liabilities-to-equity ratio. Analyzing the total debt-to-equity chart allows for a determination of the leverage level of this neuropharmacological innovator, revealing whether the debt load hinders investments in the development of safe, next-generation drugs for the treatment of anxiety disorders.
Competitor analysis
Debt to Equity Biogen|Debt to Equity Ratio NBIX (Neurocrine)|Total Debt to Capital RGC|AXSM - Debt to Capital|ACADIA Pharmaceuticals - Total Debt to Equity Ratio|Total Debt to Capital xenon-pharma.com XENE|VKTX - Debt to Equity|All Debt to Shareholders' Equity Ratio SUPN (Supernus Pharmaceuticals, Inc.)|Catalyst Pharmaceuticals Inc (CPRX) - Debt to Equity|Debt to Capital Denali Corp (DNLI)|Total Debt to Equity Ratio HRMY|Debt to Equity BHVN|Total Debt to Capital AMLX|Total Debt to Capital Coefficient Trevi Therapeutics Inc|Debt to Equity Praxis Medicines PRAX|Total Debt to Capital Coefficient Anavex Life Sciences Corp (AVXL)|CBLL: Total Debt to Equity Ratio|Prothena Corporation PLC - Aggregate Debt to Capital|ALEC: Total Debt to Capital|Annexon Biosciences (ANNX) - Total Debt to Capital|OMER (Omeros Corp) - Total Debt to Capital|NGNE - Debt to Capital Ratio|Total Debt to Capital ACIU|VYGR - Debt to Capital|Debt to Equity Neumora Therapeutics, Inc. NMRA|SCLX: Debt to Equity Ratio|TVGN: Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio ACOG (Alpha Cognition)|CGTX (Cognition Therapeutics) - Total Debt to Equity Ratio|IKT: Aggregate Debt to Capital|SAVA (Cassava Sciences) - Total Debt to Capital|ASRT: All Debt to Shareholders' Equity Ratio|Total Debt to Capital COYA|OVID - Debt to Capital|Debt to Equity Acumen Pharmaceuticals ABOS|All Debt to Shareholders' Equity Ratio CRVO|Alterity Therapeutics Ltd - Total Debt to Capital|CLNN - Total Debt to Capital|pepgen.com (PEPG) - Debt to Equity|Aggregate Debt to Equity JUNS (Jupiter Neurosciences, Inc.)|RLMD (Relmada Therapeutics) - Total Debt to Capital|Debt to Capital annovisbio.com ANVS|Total Debt to Equity Ratio GRCE (Grace Therapeutics, Inc.)|Total Debt to Capital Firefly Neuroscience, Inc. (AIFF)|Klotho Neurosciences - Total Debt to Equity Ratio|Aggregate Debt to Capital NRSN (NeuroSense Therapeutics Ltd)|Reviva Pharmaceuticals - Total Debt to Capital|Total Debt to Capital Coefficient MetaVia Inc MTVA|NRXS: Total Debt to Capital|Total Debt to Equity Ratio Helius Medical Technologies|Debt to Equity Passage Bio Inc.|Neuphoria (NEUP) - Total Debt to Capital Coefficient|Total Debt to Equity Ratio NERV (Minerva Neurosciences)|Debt to Equity ATHA (athira.com)|Addex Therapeutics Ltd - Total Debt to Equity Ratio|Aggregate Debt to Capital ALZN (Alzamend Neuro Inc.)|Cyclerion - Total Debt to Capital|Debt to Capital Ratio Protagenic Therapeutics (PTIX)|pasitheaclinics.com (KTTA) - Debt to Equity|Debt to Equity Ratio CRGT|Debt to Equity Avenue Therapeutics, Inc.|Debt to Equity Ratio BCLI (Brainstorm Cell Therapeutics Inc.)|Total Debt to Capital CARA|CHRO - Debt to Capital|Eliem Therapeutics Inc. - Total Debt to Equity Ratio|Total Debt to Capital Intra-Cellular Therapies Inc. ITCI|LBPH - Debt to Equity|All Debt to Shareholders' Equity Ratio MRNS (Marinus Pharmaceuticals Inc)|NKGen (NKGN) - Debt to Equity|Debt to Capital NeuroBo Pharma (NRBO)|Total Debt to Equity Ratio SAGE|Debt to Equity SNPX|Total Debt to Capital TRVN|Total Debt to Capital Coefficient vigilneuro.com|Debt to Equity Anew Medical WENA|Total Debt to Capital Coefficient Cerevel Corp (CERE)